However, it is necessary to address the following points: whether this strong food intake-suppressive effect is solely attributed to vigabatrin alone (without peripheral GABA involvement), whether other GABA-T inhibitors can produce effects similar to those of vigabatrin, and, importantly, whether coadministration of dietary GABA and GABA-T inhibitory drugs can exert anti-obesity effects in obese mice. Here, ABAT is linked to obesity disorder.